These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 33798211)

  • 21. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.
    Schonfeld D; Fernández H; Ramírez J; Acosta D; Becerra J; Wettstein M; Strella T; Vaccaro M; Arias S; Rodríguez Calvo V; Neme R; Pérez-Chada D
    PLoS One; 2022; 17(3):e0263679. PubMed ID: 35286328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
    Murhekar MV; Bhatnagar T; Selvaraju S; Rade K; Saravanakumar V; Vivian Thangaraj JW; Kumar MS; Shah N; Sabarinathan R; Turuk A; Anand PK; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Rangaraju C; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Salim Khan SM; Haq I; Kumar MS; Laxmaiah A; Madhuka ; Mahapatra A; Mitra A; Nirmala AR; Pagdhune A; Qurieshi MA; Ramarao T; Sahay S; Sharma YK; Shrinivasa MB; Shukla VK; Singh PK; Viramgami A; Wilson VC; Yadav R; Girish Kumar CP; Luke HE; Ranganathan UD; Babu S; Sekar K; Yadav PD; Sapkal GN; Das A; Das P; Dutta S; Hemalatha R; Kumar A; Narain K; Narasimhaiah S; Panda S; Pati S; Patil S; Sarkar K; Singh S; Kant R; Tripathy S; Toteja GS; Babu GR; Kant S; Muliyil JP; Pandey RM; Sarkar S; Singh SK; Zodpey S; Gangakhedkar RR; S Reddy DC; Bhargava B
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):48-60. PubMed ID: 32952144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.
    Castro Dopico X; Muschiol S; Christian M; Hanke L; Sheward DJ; Grinberg NF; Rorbach J; Bogdanovic G; Mcinerney GM; Allander T; Wallace C; Murrell B; Albert J; Karlsson Hedestam GB
    J Intern Med; 2021 Sep; 290(3):666-676. PubMed ID: 34008203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.
    Hajissa K; Islam MA; Hassan SA; Zaidah AR; Ismail N; Mohamed Z
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.
    Rostami A; Sepidarkish M; Leeflang MMG; Riahi SM; Nourollahpour Shiadeh M; Esfandyari S; Mokdad AH; Hotez PJ; Gasser RB
    Clin Microbiol Infect; 2021 Mar; 27(3):331-340. PubMed ID: 33228974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.
    Wagner R; Peterhoff D; Beileke S; Günther F; Berr M; Einhauser S; Schütz A; Niller HH; Steininger P; Knöll A; Tenbusch M; Maier C; Korn K; Stark KJ; Gessner A; Burkhardt R; Kabesch M; Schedl H; Küchenhoff H; Pfahlberg AB; Heid IM; Gefeller O; Überla K
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020.
    Kugeler KJ; Podewils LJ; Alden NB; Burket TL; Kawasaki B; Biggerstaff BJ; Biggs HM; Zacks R; Foster MA; Lim T; McDonald E; Tate JE; Herlihy RK; Drobeniuc J; Cortese MM
    Public Health Rep; 2022; 137(1):128-136. PubMed ID: 34752156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.
    Zaidi S; Rizwan F; Riaz Q; Siddiqui A; Khawaja S; Imam M; Naz A; Waheed S; Shamsi T
    J Public Health (Oxf); 2021 Apr; 43(1):3-8. PubMed ID: 32940328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study.
    Makaronidis J; Mok J; Balogun N; Magee CG; Omar RZ; Carnemolla A; Batterham RL
    PLoS Med; 2020 Oct; 17(10):e1003358. PubMed ID: 33001967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.
    Kaddu-Mulindwa D; Keuser L; Lesan V; Rissland J; Smola S; Werdecker V; Stilgenbauer S; Christofyllakis K; Thurner L; Bewarder M; Lohr B; Lutz J; Lohse S; Rieke A
    HIV Med; 2022 May; 23(5):564-569. PubMed ID: 34811869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020.
    Ling RJ; Yu YH; He JY; Zhang JX; Xu S; Sun RR; Zhu WC; Chen MF; Li T; Ji HL; Wang HQ
    Biomed Environ Sci; 2021 Sep; 34(9):743-749. PubMed ID: 34530966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.
    Russell TW; Golding N; Hellewell J; Abbott S; Wright L; Pearson CAB; van Zandvoort K; Jarvis CI; Gibbs H; Liu Y; Eggo RM; Edmunds WJ; Kucharski AJ;
    BMC Med; 2020 Oct; 18(1):332. PubMed ID: 33087179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Serological Snapshot of COVID-19 Initial Stages in Israel by a 6-Plex Antigen Array.
    Fisher M; Levy H; Fatelevich E; Afrimov Y; Ben-Shmuel A; Rosenfeld R; Noy-Porat T; Glinert I; Sittner A; Biber A; Belkin A; Bar-David E; Puni R; Levy I; Mazor O; Weiss S; Mechaly A
    Microbiol Spectr; 2021 Oct; 9(2):e0087021. PubMed ID: 34612689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.